Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02459119 · ClinicalTrials.gov registry record · Phase 2
Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477)
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT02459119 is a Phase 2 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 17 participants.
The verdict
NCT02459119, a Phase 2 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
This study will test how well Regorafenib controls disease progression in urothelial cancer (cancer occurring in the urinary bladder, ureters, or renal pelvis) following previous therapy with chemotherapy.
Interventions
- DRUG Regorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2015-05 |
| Est. Completion | 2020-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02459119
The ClinicalTrials.gov registry entry for NCT02459119 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Regorafenib is the first listed.
NCT02459119 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02459119 about?
NCT02459119 is a clinical study titled "Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477)". This study will test how well Regorafenib controls disease progression in urothelial cancer (cancer occurring in the urinary bladder, ureters, or renal pelvis) following previous therapy with chemotherapy.
What is the current status of trial NCT02459119?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2015-05. Estimated completion is 2020-04.
What interventions are being tested in trial NCT02459119?
The interventions under investigation include: Regorafenib (DRUG).
Who is sponsoring clinical trial NCT02459119?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.